The Washington Department of Health is reviewing a complaint that Sun Pharmaceuticals (SUNPHARMA) has been distributing samples of medicines in the state for more than two years without the necessary license, the second time one of the world’s largest generic drug makers has been probed for such an infraction amid scrutiny of several of its business practices.

A department spokeswoman explained that the complaint is currently being reviewed, but this is in the “very early stages of the process” and that the state Pharmacy Commission must still determine whether there is sufficient evidence to warrant a full-blown investigation. She did not say, though, how long this may take or whether a timeline exists to make a decision.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Since last few years, Sun is found in some or other controversies. Despite this, no brokerage house is giving any red signal to this stock. This creates their vested interest or some kind of hand in glove connivance with the management.

  • MANY COMPETITORS OF SUN PHARMA ARE POSSIBLY INVOLVED IN CLANDESTINE ACTIVITIES OF PULLING DOWN SUN PHARMA BY RUMOR SPREADING & MANIPULATING CONTINUATION OF SOME OR OTHER MINOR ISSUES DURING INSPECTION. FALSEHOOD CAN EXIST FOR SOMETIMES BUT ULTIMATELY TRUTH ONLY WILL PREVAIL AND SUN(PHARMA) WILL SHOW IT’S SUPREMACY.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy